(Albany, USA) DelveInsight’s “Diabetic retinopathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diabetic retinopathy, historical and forecasted epidemiology as well as the Diabetic retinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

To know more about the Diabetic retinopathy market analysis, click here @ Diabetic retinopathy market forecast

 

Key takeaways from the Diabetic Retinopathy Market Report

• The Diabetic retinopathy market size in the seven major markets was found to be USD 126,851 million in 2021.
•  The total Diabetic Retinopathy prevalent cases in the 7MM were 12,585,769 in 2021.
• The leading Diabetic Retinopathy Market Companies include Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., and others.
• Promising Diabetic Retinopathy Pipeline Therapies include PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Latanoprost, Lucentis, Octreotide Acetate in Microspheres 20 mg, KSI-301, and others.

 

Diabetic Retinopathy Overview

Diabetic retinopathy (DR) is a common and specific microvascular complication of diabetes and remains the leading cause of preventable blindness in working-aged people. It is identified in a third of people with diabetes and is associated with increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure. In the USA, an estimated 40% (8% for vision-threatening retinopathy) of people with type 2 diabetes and 86% (42%) with type 1 diabetes have diabetic retinopathy.

 

Request for Diabetic retinopathy sample report @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

 

Diabetic Retinopathy Epidemiology Segmentation in the 7MM

• Total Diabetic Retinopathy Prevalent cases
• Diabetic Retinopathy Gender-specific
• Diabetic Retinopathy Severity-specific cases
• Diabetic Retinopathy Age-specific cases

 

Recent Developmental Activities in the Diabetic Retinopathy Treatment Landscape

• In May 2022, EyePoint Pharmaceuticals announced the EYP-1901 license to Betta Pharmaceuticals, to develop and commercialize EYP-1901 in China, Hong Kong, Macau, and Taiwan. EyePoint retains all rights for EYP-1901 in the rest of the world and expands its exclusive rights to local delivery of vorolanib for the treatment of all ophthalmic diseases, including diabetic macular edema (DME). Phase 2 clinical trial for EYP-1901 in non-proliferative diabetic retinopathy (NPDR) is expected to initiate in 2H 2022.
• In April 2022, Ocuphire Pharma presented masked safety data from the ongoing ZETA-1 Phase 2b trial of oral APX3330 for the treatment of diabetic retinopathy. The results show a favorable ophthalmic and systemic safety and tolerability profile, consistent with 11 prior safety trials of APX3330 in non-ophthalmic indications. The company expects to report top-line results from the ZETA-1 trial in the second half of 2022.
• In January 2022, Ocuphire Pharma entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications.
• The Therapeutic candidate KSI-301, currently in clinical development being produced by Kodiak Sciences is a novel anti-VEGF biologic designed to have an extended ocular half-life. KSI-301 is being developed in Phase III stage of Diabetic Retinopathy Pipeline development towards a once every four to six-month treatment regimen – a possible game changer that may provide the opportunity for real prevention.
• Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment developed by Novartis. Currently, it is in the Phase III stage of development to treat Diabetic Retinopathy.

 

To know more about Diabetic Retinopathy Emerging Drugs & Companies, visit @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

 

Diabetic Retinopathy Emerging Drugs Profile

• OPT-302: Opthea Limited

OPT-302 is a first-in-class VEGF-C/D inhibitor. It is a soluble fusion protein comprising immunoglobulin-like domains 1 to 3 of the extracellular domain of vascular endothelial growth factor receptor 3 (VEGFR-3) fused to the Fc fragment of human immunoglobulin G1 (IgG1) (Opthea, 2019). OPT-302 is a soluble form of VEGFR-3 which binds (“traps”) human VEGF-C and VEGF-D with high affinity, neutralizing their activity by preventing them from binding to both VEGFR-2 and VEGFR-3 (Opthea, 2019). 

• RGX 314: Regenxbio

It is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the fluid accumulation in the retina. 

• Runcaciguat (BAY 1101042): Bayer

The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is a key regulator of body and tissue homeostasis. sGC activators with their unique mode of action are activating the oxidized and heme-free and therefore NO-unresponsive form of sGC, which is formed under oxidative stress. Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy (Hahn et al., 2021).

Diabetic Retinopathy Market Dynamics

The Diabetic Retinopathy market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world. The launch of several emerging therapies is expected during the forecast period of 2022-2032. The pipeline of Diabetic Retinopathy is quite robust with several products available in the developmental stage. There are several key players involved in the development of promising products such as Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., and others.

 

Learn more about the Diabetic Retinopathy Pipeline Therapies in clinical trials @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

 

Scope of the Diabetic Retinopathy Market Report

• Coverage- 7MM
• Diabetic Retinopathy Companies- Regeneron Pharmaceuticals (NYSE: REGN), Roche NYSE: ROG), Opthea Limited (NYSE: OPT), Regenxbio (NYSE: RGNX), Kodiak Sciences Inc (NYS: KOD), Ocuphire Pharma (NYSE: OCUP), Eisai Co Ltd (NYSE: ESALY), Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals (NYSE: NVS), Allegro Ophthalmics LLC, Adverum Biotechnologies Inc, (NYSE: ADVM), Graybug Vision (NYSE: GRAY), Kubota Vision Inc (NYSE: KUBTY)., KalVista Pharmaceuticals Ltd (NYSE: KALV), and others.
• Diabetic Retinopathy Pipeline Therapies- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Latanoprost, Lucentis, Octreotide Acetate in Microspheres 20 mg, KSI-301, and others.
• Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy Market Drivers and Barriers
• Diabetic Retinopathy Market Access and Reimbursement, Unmet Needs, Future Perspectives

 

Discover more about Diabetic Retinopathy Drugs in development @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

 

Table of Content

1. Key Insights
2. Diabetic Retinopathy Report Introduction
3. Diabetic Retinopathy Market Overview at a Glance
4. Executive Summary of Diabetic Retinopathy
5. Disease Background and Overview
6. Management and Treatment
7. Diabetic Retinopathy Epidemiology and Patient Population
8. Patient Journey 1
9. Patient Journey 2
10. Diabetic Retinopathy Marketed Drugs
11. Diabetic Retinopathy Emerging Drugs
12. Other Therapy
13. Diabetic Retinopathy: Seven Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting